POMS: A Clinical View

Volume 6, Issue 2

POMS: A Clinical View

In this issue:

POMS. Pediatric Onset Multiple Sclerosis: children and adolescents with symptoms indicating a diagnosis of multiple sclerosis. Are their presentations different from adult-onset MS? POMS is often associated with higher degrees of activity and inflammation early in the disease. How can clinicians most effectively confirm an early MS diagnosis in these young patients? What does the current evidence show about when to prescribe high-efficacy disease modifying therapies? What activity limitations should be placed on patients with POMS?

Join us, as Dr. Haiwen Chen and Dr. Karla Gray-Roncal — two MS specialists from the Johns Hopkins University School of Medicine — discuss POMS from a clinical perspective, in this issue of eMultipleSclerosis Review.

Learning objective:

Discuss evidence that informs treatment decisions for pediatric patients.

Authors:

Haiwen Chen, MD, PhD

Assistant Professor of Neurology
Johns Hopkins University School of Medicine

Karla Gray-Roncal, MD

Fellow in Neuroimmunology and Neurological Infectious Disease (NMSS Sylvia Lawry Fellow)
Johns Hopkins University School of Medicine

Guest Faculty Disclosures

The authors have indicated that they have no financial interests or relationships with an ineligible company.  

Unlabeled/Unapproved Uses

The authors made the following references to disease modifying therapies currently used off-label for treating POMS: interferon beta, glatiramer acetate, dimethyl fumarate, diroximel fumarate, teriflunomide, natalizumab, rituximab, ocrelizumab, alemtuzumab, and cyclophosphamide.

Program Directors:

Michael Kornberg, MD, PhD

Assistant Professor
Department of Neurology
Johns Hopkins School of Medicine
Baltimore, MD

Pavan Bhargava, MBBS, MD

Assistant Professor
Department of Neurology
Johns Hopkins School of Medicine
Baltimore, MD

Lisa Fox, PA-C, MPAS

Department of Neurology
Johns Hopkins Hospital
Baltimore, MD

Guest Faculty Disclosures:

The authors have indicated that they have no financial interests or relationships with an ineligible company.  

Unlabeled/Unapproved Uses:

Length of activity:

0.5 hour Physicians
0.5 contact hour Nurses

Launch date: September 15, 2024
Expiration date: September 14, 2026

Start Issue